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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Canadian varieties 
of English and French. The reading comprehension of the questionnaires were tested in a probe sample of ten parents and 
ten JIA patients for Canadian English and other ten parents and ten JIA patients for Canadian French. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability and construct validity 
(convergent and discriminant validity). A total of 208 JIA patients (2.9% systemic, 41.8% oligoarticular, 27.9% RF negative 
polyarthritis, 27.4% other categories) and 152 healthy children, were enrolled at two paediatric rheumatology centres. The 
JAMAR components discriminated well healthy subjects from JIA patients. Notably, there was no significant difference 
between the healthy subjects and their affected peers in the psychosocial quality of life variable. All JAMAR components 
revealed good psychometric performances. In conclusion, the Canadian English and French versions of the JAMAR are valid 
tools for the assessment of children with JIA and are suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Canadian English and French parent, child/
adult version of the Juvenile Arthritis Multidimensional 
Assessment Report (JAMAR) [1] in patients with juvenile 
idiopathic arthritis (JIA). The JAMAR assesses the most 
relevant parent/patient reported outcomes in JIA, including 
overall well-being, functional status, health related quality 
of life (HRQoL), pain, morning stiffness, disease activity/
status/course, articular and extra-articular involvement, 
drug-related side effects/compliance and satisfaction with 
illness outcome.
This project was part of a larger multinational study 
conducted by the Paediatric Rheumatology International 
Trials Organisation (PRINTO) [2] aimed to evaluate the 
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Epidemiology, Outcome and Treatment of Childhood 
Arthritis (EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Canadian varieties of English and French.
Materials and methods
The methodology employed has been described in detail 
in the introductory paper of the supplement [4]. In brief, 
it was a cross-sectional study of JIA children, classified 
according to the ILAR criteria [5, 6] and enrolled from 
February 2012 to June 2016. Children were recruited after 
Ethics Committee approval and consent from at least one 
parent.
The JAMAR
The JAMAR (1) includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale);
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten parents and 
ten JIA patients for Canadian English and other ten parents 
and ten JIA patients for Canadian French.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption [mean and standard deviation (SD) equiva-
lence]; the second Likert assumption or equal items–scale 
correlations (Pearson r: all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
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the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Canadian English and French translations 
of JAMAR (parent and patient versions) are available upon 
request to PRINTO.
Results
Cross cultural adaptation
The Canadian English JAMAR was fully cross-culturally 
adapted from the original standard English version of the 
questionnaire with no forward and backward translation.
The Canadian French JAMAR was fully cross-culturally 
adapted from the Swiss French version performed by the 
PRINTO centre in Switzerland with no forward and back-
ward translation.
With regard to the Canadian English JAMAR, all 123 
lines of the parent version of the JAMAR were understood 
by at least 80% of the 10 parents tested (median 100%; range 
90–100%) and all the 120 lines of the patient version of the 
JAMAR were understood by at least 80% of the children 
(median 100%; range 100–100%). The parent and child ver-
sions of the Canadian English were unmodified after the 
probe technique.
With regard to the Canadian French JAMAR, of the 123 
lines in the parent version of the JAMAR, 122 (99.2%) were 
understood by at least 80% of the 10 parents tested (median 
100%; range 70–100%). All the 120 lines of the patient ver-
sion of the JAMAR were understood by at least 80% of the 
children (median 100%; range 80–100%). Line 54 in the 
parent version of the JAMAR was modified according to par-
ent’s suggestions; the child versions of the Canadian English 
was unmodified after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 208 JIA patients and 152 healthy children (total of 
360 subjects), were enrolled at two paediatric rheumatology 
centres in Canada.
In the 208 JIA subjects, the JIA categories were 2.9% with 
systemic arthritis, 41.8% with oligoarthritis, 27.9% with RF 
negative polyarthritis, 2.9% with RF positive polyarthritis, 
4.3% with psoriatic arthritis, 10.6% with enthesitis-related 
arthritis and 9.6% with undifferentiated arthritis (Table 1).
A total of 354/360 (98.3%) subjects had the parent ver-
sion of the JAMAR completed by a parent (206 from parents 
of JIA patients and 148 from parents of healthy children). 
The JAMAR was completed by 296/354 (83.6%) mothers 
and 58/354 (16.4%) fathers. The child version of the JAMAR 
was completed by 307/360 (85.3%) children age 6.8 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in HRQoL PsH variable.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses was 3.9% (3.9–4.4%). The response pattern for 
both PF and HRQoL was positively skewed toward normal 
functional ability and normal HRQoL. All response choices 
were used for the different HRQoL items except for item 1, 
whereas a reduced number of response choices was used for 
all the PF items with the exception of items 1, 3, 4, and 13.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 1% (1–3%) for the PF and 7% (3–8%) for 
the HRQoL.
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Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 208 JIA patients
Data related to the JAMAR refers to the 206 JIA patients and to the 148 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL Health Related Quality of Life (total score ranges from 0 to 30), PhH Physical Health (total score ranges 
from 0 to 15), PsH Psychosocial Health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic 
(N = 6)
Oligoarthritis 
(N = 87)
RF-poly-
arthritis 
(N = 58)
RF + poly-
arthritis 
(N = 6)
Psoriatic 
arthritis 
(N = 9)
Enthesitis 
related 
arthritis 
(N = 22)
Undifferenti-
ated arthritis 
(N = 20)
All JIA 
patients 
(N = 208)
Healthy 
(N = 152)
Female 6 (100%) 56 (64.4%) 44 (75.9%) 5 (83.3%) 6 (66.7%) 10 (45.5%) 10 (50%) 137 (65.9%)* 78/145 
(53.8%)*
Age at visit 11.7 
(9.2–13.5)
13 (9.5–15.1) 12.8 (10.4–
14.7)
15.2 (12.5–
17.1)
11.5 
(7.1–16.3)
13.4 
(11–16.1)
14.7 (10.6–
16.2)
13.2 (10.2–
15.4)
11.6 (9.4–
13.5)**
Age at onset 6.6 (4.4–8.7) 5.5 (2.3–9.6) 6.9 (2.7–
10.4)
12.5 (10.3–
15.2)
5 (1.7–7.7) 9.3 (6.8–
10.9)
7.9 (3.9–
11.9)
6.9 (3–10.3)**
Disease duration 3.7 (0.5–6.6) 5.1 (2.1–9.3) 4.4 (1.7–7.7) 1.5 (0.7–4.4) 6.8 (2.6–7.9) 3.9 (2–7.1) 4.6 (2.7–7) 4.7 (1.9–8.3)
ESR 7 (1–15) 7 (4.5–14) 7 (1–21) 14 (12–19) 40 (20–45) 3 (1–24) 6 (4–17) 8 (3–19)
MD VAS 
(0–10 cm)
0 (0–0) 0 (0–2) 1 (0–3.5) 3 (0–5) 0.5 (0–2.5) 1.5 (0–3.5) 0 (0–2) 0 (0–3)
No. of swollen 
joints
0 (0–0) 0 (0–1) 0 (0–3) 0.5 (0–7) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1)
No. of joints with 
pain
0 (0–0) 0 (0–1) 0 (0–2) 0 (0–2) 0 (0–0) 0 (0–2) 0 (0–1.5) 0 (0–1)
No. of joints with 
LOM
0 (0–0) 0 (0–1) 2 (0–4) 8 (4–17) 0 (0–0) 0.5 (0–2) 0 (0–1.5) 0 (0–2)**
No. of active 
joints
0 (0–0) 0 (0–1) 1 (0–4) 0.5 (0–7) 0 (0–1) 0 (0–2) 0 (0–2) 0 (0–2)
Active systemic 
features
1 (16.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (5%) 2 (1%)
ANA status 0 (0%) 2 (2.3%) 2 (3.4%) 0 (0%) 0 (0%) 1 (4.5%) 1 (5%) 6 (2.9%)
Uveitis 0 (0%) 16/86 
(18.6%)
6/56 (10.7%) 0 (0%) 0 (0%) 0 (0%) 1 (5%) 23/204 
(11.3%)*
PF total score 0 (0–0) 0 (0–3) 1 (0–5) 0 (0–3) 0 (0–2) 2 (0–6) 0 (0–2) 0 (0–4)* 0 (0–0)#
Pain VAS 0 (0–0) 0 (0–1) 1 (0–5) 0.5 (0–1) 0 (0–0) 1 (0–3) 0 (0–0) 0 (0–2) 0 (0–0)#
Disease activity 
VAS
0 (0–0) 0 (0–2.5) 1 (0–7) 2.5 (0–5) 0 (0–0) 1 (0–8) 1 (0–3) 0 (0–3)
Well-being VAS 0 (0–0) 0 (0–2) 0.5 (0–2.5) 1 (0–1) 0 (0–2) 0 (0–2.5) 0 (0–4) 0 (0–2)
HRQoL PhH 0 (0–1) 1 (0–4) 2 (1–5) 2 (0–5) 0 (0–2) 2 (0–4) 1.5 (0–3) 1.5 (0–4) 0 (0–1)#
HRQoL PsH 1 (0–5) 1 (0–3) 1 (0–4) 1.5 (0–3) 0 (0–0) 1 (0–4) 1 (0–3.5) 1 (0–3) 0 (0–3)
HRQoL total 
score
1 (0–6) 2 (0–6) 4.5 (1–10) 4 (2–5) 0 (0–4.5) 6 (0–8) 3 (1–6) 3 (0–8) 0 (0–3)#
Pain/swell. in > 1 
joint
0 (0%) 36/86 
(41.9%)
29 (50%) 4 (66.7%) 3 (33.3%) 10/21 
(47.6%)
11 (55%) 93/206 (45.1%) 9/148 (6.1%)#
Morning stiff-
ness > 15 min
0 (0%) 17/85 (20%) 11/54 
(20.4%)
2 (33.3%) 1/6 (16.7%) 8/21 (38.1%) 4 (20%) 43/198 (21.7%) 0 (0%)#
Subjective remis-
sion
1 (16.7%) 33/83 
(39.8%)
28/54 
(51.9%)
3 (50%) 2/6 (33.3%) 14/21 
(66.7%)
9 (45%) 90/196 (45.9%)
In treatment 6 (100%) 61/85 
(71.8%)
49/54 
(90.7%)
6 (100%) 4/6 (66.7%) 17/20 (85%) 15 (75%) 158/197 
(80.2%)
Reporting side 
effects
1 (16.7%) 16/61 
(26.2%)
27/49 
(55.1%)
0 (0%) 1/4 (25%) 4/17 (23.5%) 8/14 (57.1%) 57/157 
(36.3%)*
Taking medica-
tion regularly
5 (83.3%) 54/61 
(88.5%)
46/49 
(93.9%)
5 (83.3%) 3/4 (75%) 13/17 
(76.5%)
13/15 
(86.7%)
139/158 (88%)
With problems 
attending school
1/5 (20%) 9/59 (15.3%) 3/32 (9.4%) 1/5 (20%) 0 (0%) 6/14 (42.9%) 2/12 (16.7%) 22/131 (16.8%) 0 (0%)#
Satisfied with dis-
ease outcome
6 (100%) 68/85 (80%) 39/53 
(73.6%)
3 (50%) 5/6 (83.3%) 15/21 
(71.4%)
14 (70%) 150/197 
(76.1%)
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Floor and ceiling effect
The median floor effect was 85.4% (79.1–90.8%) for the PF 
items, 65.5% (58.3–67.5%) for the HRQoL physical health 
(PhH) items, and 64.1% (63.1–67%) for the HRQoL psy-
chosocial health (PsH) items. The median ceiling effect was 
0% (0–0.5%) for the PF items, 1% (1–4.4%) for the HRQoL 
PhH items, and 1% (0.5–1%) for the HRQoL PsH items. The 
median floor effect was 40.3% for the pain VAS, 38.3% for 
the disease activity VAS and 42.7% for the well-being VAS. 
The median ceiling effect was 0.5% for the pain VAS, 2.9% 
for the disease activity VAS and 0% for the well-being VAS.
Equal items–scale correlations (second Likert 
assumption)
Pearson items–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the 
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiophatic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL Health Related Quality of Life, PhH Physical Health, PsH Psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent (N = 206/354) Child (N = 172/307)
Missing values (1st–3rd quartiles) 3.9 (3.9–4.4) 0.0 (0.0–0.6)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 85.4% 90.1%
 HRQoL PhH 65.5% 73.3%
 HRQoL PsH 64.1% 72.7%
 Pain VAS 40.3% 38.4%
 Disease activity VAS 38.3% 40.1%
 Well-being VAS 42.7% 48.8%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 1.0% 1.7%
 HRQoL PsH 1.0% 1.2%
 Pain VAS 0.5% 0.0%
 Disease activity VAS 2.9% 1.7%
 Well-being VAS 0.0% 0.6%
Items with equivalent item-scale correlation 93% for PF, 90% for HRQoL 87% for PF, 80% for HRQoL
Items with items–scale correlation ≥ 0.4 87% for PF, 90% for HRQoL 87% for PF, 80% for HRQoL
Cronbach’s alpha
 PF-LL 0.87 0.89
 PF-HW 0.84 0.86
 PF-US 0.67 0.59
 HRQoL-PhH 0.81 0.85
 HRQoL-PsH 0.86 0.74
Items with item-scale correlation lower than the Cronbach alpha 93% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.97 0.99
 HRQoL PhH 1.0 1.0
 HRQoL PsH 1.0 0.79
Spearman correlation with JIA core-set variables, median
 PF 0.5 0.5
 HRQoL PhH 0.5 0.5
 HRQoL PsH 0.4 0.3
 Pain VAS 0.4 0.4
 Disease activity VAS 0.4 0.2
Well-being VAS 0.3 0.3
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PF items, with the exception of PF item 14, and for 90% of 
the HRQoL items, with the exception of HRQoL item 1.
Items internal consistency (third Likert assumption)
Pearson items–scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for items 11 and 15) and 90% of items of 
the HRQoL (except for item 1).
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.87 for PF-LL, 0.84 for PF-HW, 0.67 
for PF-US. Cronbach’s alpha was 0.81 for HRQoL-PhH and 
0.86 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha, with 
the exception of PF item 14.
Test–retest reliability
Reliability was assessed in 18 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 5.5 days (4–7 days). The intraclass correlation 
coefficients (ICC) for the PF total score showed an almost 
perfect reproducibility (ICC 0.97). The ICC for the HRQoL 
PhH score and for the HRQoL PsH score showed an almost 
perfect reproducibility (ICC 1.0 for both).
Convergent validity
The Spearman correlation of the PF total score with the JIA 
core set of outcome variables ranged from 0.4 to 0.6 (median 
0.5). The PF total score best correlation was observed with 
the parent’s assessment of pain (r = 0.7, p < 0.001). For the 
HRQoL, the median correlation of the PhH with the JIA 
core set of outcome variables ranged from 0.3 to 0.7 (median 
0.5), whereas for the PsH ranged from 0.2 to 0.6 (median 
0.4). The PhH showed the best correlation with the parent’s 
assessment of pain (r = 0.8, p < 0.001) and the PsH with the 
parent global assessment of well-being (r = 0.6, p < 0.001). 
The median correlations between the pain VAS, the well-
being VAS, and the disease activity VAS and the physician-
centred and laboratory measures were 0.4 (0.2–0.5), 0.4 
(0.3–0.5), 0.3 (0.2–0.4), respectively.
Discussion
In this study, the Canadian English JAMAR was fully cross-
culturally adapted from the original standard English version 
with no forward and backward translation and the Canadian 
French JAMAR was fully cross-culturally adapted from the 
Swiss French version performed by the PRINTO centre in 
Switzerland with no forward and backward translation.
According to the results of the validation analysis, the 
Canadian parent and patient versions of the JAMAR pos-
sess satisfactory psychometric properties. The disease-spe-
cific components of the questionnaire discriminated well 
between patients with JIA and healthy controls. Notably, 
there was no significant difference between the healthy 
subjects and their affected peers in the psychosocial qual-
ity of life variable. This finding indicates that children 
with JIA adapt well to the consequences of JIA.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: PF items 11 and 15 
(“stretch out arms” and “bite a sandwich or an apple”) and 
HRQoL item 1 (“Difficulty of taking care of him/herself”) 
showed a lower items internal consistency. However, the 
overall internal consistency was at least acceptable for all 
the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters range from weak to moderate.
When we analyze the data of the JAMAR questionnaire 
separately, dividing the French-speaking population from 
the Engligh one, the results were substantially overlapping 
(data not shown).
The statistical performances of the child version of the 
JAMAR are very similar to those obtained by the parent 
version, which suggests that children are reliable reporters 
of their disease and health status.
The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care.
In conclusion, the Canadian English and French versions 
of the JAMAR were found to have satisfactory psychometric 
properties and represent, thus, reliable and valid tools for the 
multidimensional assessment of children with JIA.
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